Swen W.
- Country
- Germany
- Department
- Cancer Center Esslingen
Research Overview
- A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)
- Evaluation of Daratumumab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone for Transplant-Ineligible Multiple Myeloma Patients
- Phase III Randomized Trial of Decitabine, Venetoclax, and Tretinoin in Acute Myeloid Leukemia Patients Ineligible for Induction Chemotherapy
Data & Insights
Has run more than one trial at 114 of 310 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various blood cancers, with particular emphasis on multiple myeloma and chronic lymphocytic leukemia. Their research encompasses innovative therapeutic approaches for these conditions.
- Multiple Myeloma Management
- Chronic Lymphocytic Leukemia (CLL) Treatment
- Small Lymphocytic Lymphoma (SLL) Care
Lymphoma Studies
The investigator focuses on advanced treatments for various types of lymphoma, particularly diffuse large B-cell lymphoma and Hodgkin lymphoma. Their work includes specialized approaches for elderly patients.
- B-Cell Lymphoma Variants
- Advanced Stage Hodgkin Lymphoma
- Age-Adapted Treatment Protocols
Leukemia and Myeloid Disorders
Their expertise extends to treating acute myeloid leukemia and myelodysplastic syndromes, with particular interest in developing treatment strategies for patients with specific genetic profiles.
- Acute Myeloid Leukemia Treatment
- Myelodysplastic Syndromes Management
- Genetic Risk-Based Therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.